The initial pharmacotherapy of ER+ breast cancer commonly includes prescribing of an aromatase inhibitor, an ER antagonist, a selective ER modulator (SERM), or a CDK4/6 inhibitor [2]. Here, ESR1 is linked to breast cancer.